Patent ID: 7968518

Claim:
A method for inhibiting HCV replication in a medium, comprising applying to said medium an effective amount of a cyclosporin according to formula Ia: in which W′ is MeBmt, dihydro-MeBmt or 8′-hydroxy-MeBmt; X is αAbu, Val, Thr, Nva, or O-methyl threonine (Me-O-Thr); R′ is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(O-Acetyl); Y′ is MeLeu, γ-hydroxy-MeLeu, MeVal, Melle, MeThr, MeAla; Mealle or MeaThr; N-ethylVal, N-ethyllle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(O-Acetyl) Z is Val, Leu, MeVal or MeLeu; and Q′ is MeLeu, γ-hydroxy-MeLeu or MeAla, or a pharmaceutically acceptable salt thereof, wherein the cyclosporin (i) binds to human recombinant cyclophilin with a binding ratio (BR) of less than 0.7, BR being the log to base 10 of the ratio of the IC 50 of the cyclosporin to the IC 50 of cyclosporin A as measured in a competitive ELISA test; and (ii) has an activity in the Mixed Lymphocyte Reaction (MLR) of not more than 5% that of cyclosporin A.